Chemometec As Stock Beta
| CHEMM Stock | DKK 473.60 6.40 1.33% |
ChemoMetec AS fundamentals help investors to digest information that contributes to ChemoMetec's financial success or failures. It also enables traders to predict the movement of ChemoMetec Stock. The fundamental analysis module provides a way to measure ChemoMetec's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ChemoMetec stock.
ChemoMetec |
ChemoMetec AS Company Beta Analysis
ChemoMetec's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current ChemoMetec Beta | 1.37 |
Most of ChemoMetec's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ChemoMetec AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, ChemoMetec AS has a Beta of 1.3744. This is 29.66% higher than that of the Life Sciences Tools & Services sector and 26.09% higher than that of the Health Care industry. The beta for all Denmark stocks is notably lower than that of the firm.
ChemoMetec Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ChemoMetec's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ChemoMetec could also be used in its relative valuation, which is a method of valuing ChemoMetec by comparing valuation metrics of similar companies.ChemoMetec is currently under evaluation in beta category among its peers.
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, ChemoMetec will likely underperform.
ChemoMetec Fundamentals
| Return On Equity | 0.49 | |||
| Return On Asset | 0.31 | |||
| Profit Margin | 0.39 % | |||
| Operating Margin | 0.50 % | |||
| Current Valuation | 14.38 B | |||
| Shares Outstanding | 17.4 M | |||
| Shares Owned By Insiders | 10.87 % | |||
| Shares Owned By Institutions | 51.35 % | |||
| Price To Earning | 197.96 X | |||
| Price To Book | 40.83 X | |||
| Price To Sales | 32.10 X | |||
| Revenue | 428.39 M | |||
| Gross Profit | 384.25 M | |||
| EBITDA | 224.86 M | |||
| Net Income | 159.47 M | |||
| Cash And Equivalents | 209.02 M | |||
| Cash Per Share | 12.01 X | |||
| Total Debt | 6.79 M | |||
| Debt To Equity | 0.02 % | |||
| Current Ratio | 2.57 X | |||
| Book Value Per Share | 26.27 X | |||
| Cash Flow From Operations | 176.86 M | |||
| Earnings Per Share | 10.15 X | |||
| Target Price | 1000.0 | |||
| Number Of Employees | 162 | |||
| Beta | 1.37 | |||
| Market Capitalization | 8.48 B | |||
| Total Asset | 501.27 M | |||
| Retained Earnings | 36 M | |||
| Working Capital | 25 M | |||
| Current Asset | 33 M | |||
| Current Liabilities | 8 M | |||
| Annual Yield | 0 % | |||
| Net Asset | 501.27 M |
About ChemoMetec Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ChemoMetec AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ChemoMetec using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ChemoMetec AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with ChemoMetec
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ChemoMetec position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ChemoMetec will appreciate offsetting losses from the drop in the long position's value.Moving against ChemoMetec Stock
| 0.49 | JYSK | Jyske Bank AS | PairCorr |
| 0.38 | KLEE-B | Brd Klee AS | PairCorr |
| 0.36 | GMAB | Genmab AS | PairCorr |
| 0.35 | FYNBK | Fynske Bank AS | PairCorr |
| 0.34 | LOLB | Lollands Bank | PairCorr |
The ability to find closely correlated positions to ChemoMetec could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ChemoMetec when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ChemoMetec - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ChemoMetec AS to buy it.
The correlation of ChemoMetec is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ChemoMetec moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ChemoMetec AS moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ChemoMetec can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Other Information on Investing in ChemoMetec Stock
ChemoMetec financial ratios help investors to determine whether ChemoMetec Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ChemoMetec with respect to the benefits of owning ChemoMetec security.